Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Reaffirmed by Rodman & Renshaw

Rodman & Renshaw reaffirmed their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a report released on Tuesday, Benzinga reports. Rodman & Renshaw currently has a $14.00 target price on the stock.

Several other analysts have also issued reports on CGTX. B. Riley restated a buy rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a report on Thursday, March 28th. HC Wainwright began coverage on Cognition Therapeutics in a research note on Wednesday, May 29th. They set a buy rating and a $10.00 price target on the stock. Chardan Capital initiated coverage on Cognition Therapeutics in a research report on Thursday, June 6th. They issued a buy rating and a $11.00 target price for the company. Finally, Oppenheimer reissued an outperform rating and set a $9.00 price target on shares of Cognition Therapeutics in a research report on Wednesday, March 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of Buy and a consensus target price of $9.17.

Cognition Therapeutics Stock Down 2.7 %

Shares of NASDAQ:CGTX opened at $1.77 on Tuesday. Cognition Therapeutics has a 52-week low of $0.90 and a 52-week high of $2.95. The business has a fifty day moving average of $2.00 and a two-hundred day moving average of $2.00. The stock has a market cap of $70.91 million, a P/E ratio of -1.92 and a beta of 1.47.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities analysts anticipate that Cognition Therapeutics will post -0.97 earnings per share for the current year.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics during the 1st quarter worth approximately $47,000. Sigma Planning Corp purchased a new stake in Cognition Therapeutics during the 4th quarter worth about $53,000. Levin Capital Strategies L.P. purchased a new position in shares of Cognition Therapeutics in the 1st quarter valued at about $55,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Cognition Therapeutics during the 4th quarter worth about $102,000. Finally, Twin Focus Capital Partners LLC purchased a new stake in Cognition Therapeutics during the fourth quarter worth approximately $173,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.